- Raw materials
- Antidepressants
- Tricyclic antidepressants
- Opipramol DiHydrochloride
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Opipramol DiHydrochloride API Manufacturers & Suppliers
3 verified results
Commercial-scale Suppliers
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Urapidil | CAS No: 34661-75-1 | GMP-certified suppliers
A medication that targets hypertension management in pre-eclampsia by providing peripheral vasodilation and central sympathetic modulation.
Therapeutic categories
Product Snapshot
- Urapidil is available in multiple formulation types including oral capsules, extended-release capsules, and injectable solutions for intravenous administration
- It is primarily used for antihypertensive therapeutic applications
- Urapidil is currently in the investigational stage and has not received regulatory approval from major markets such as the FDA or EMA
Clinical Overview
Pharmacologically, urapidil is classified under several adrenergic-related categories, including alpha-1 adrenergic receptor antagonists and antiadrenergic agents. Its activity suggests peripheral vasodilation through antagonism of peripheral alpha-1 receptors, contributing to blood pressure reduction. Additionally, evidence categorizes it as a serotonin receptor agonist and a central nervous system depressant, indicating potential modulation of central sympathetic outflow and vascular tone. However, specific detailed pharmacodynamics and the precise molecular mechanism of action have not been explicitly defined in available data.
Absorption, distribution, metabolism, and excretion parameters for urapidil have not been well characterized in publicly available literature. The investigational status implies that comprehensive ADME profiles, including bioavailability, metabolic pathways, half-life, and elimination routes, are either limited or under ongoing evaluation.
Safety and toxicity data remain incomplete due to its investigational use. Known drug classes associated with urapidil suggest caution regarding hypotension, central nervous system effects, and potential interactions with other cardiovascular or serotonergic agents. The clinical context of hypertension management in pre-eclampsia necessitates careful monitoring given the vulnerable patient population.
Urapidil is not widely marketed globally and is considered investigational without broad regulatory approvals. Usage is typically confined to clinical research settings, with limited brand associations.
For pharmaceutical development and API sourcing, careful evaluation of the compound’s synthetic route, purity specifications, and stability profiles is crucial. Given the lack of extensive commercial availability and regulatory approval, sourcing from qualified suppliers with validated quality control measures is essential to ensure compliance with regulatory standards and to support investigational use.
Identification & chemistry
| Generic name | Urapidil |
|---|---|
| Molecule type | Small molecule |
| CAS | 34661-75-1 |
| UNII | A78GF17HJS |
| DrugBank ID | DB12661 |
Formulation & handling
- Urapidil is available for both oral administration (including extended-release capsules) and parenteral use via intravenous injection.
- As a small molecule with moderate water solubility and a phenylpiperazine structure, standard handling precautions for small molecules apply without special biologic considerations.
- Formulations for injection require attention to concentration and solution stability suitable for parenteral administration.
Regulatory status
Opipramol DiHydrochloride is a type of Tricyclic antidepressants
Tricyclic antidepressants (TCAs) are a class of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the treatment of various mental health disorders, especially depression and anxiety. TCAs derive their name from their unique molecular structure, which consists of three interconnected rings.
These antidepressants work by inhibiting the reuptake of neurotransmitters such as serotonin and norepinephrine in the brain, thereby increasing their availability and improving mood regulation. Some commonly prescribed TCAs include amitriptyline, imipramine, and nortriptyline.
The efficacy of TCAs in managing depressive symptoms is well-documented, making them a popular choice among healthcare professionals. Additionally, they exhibit analgesic properties, making them useful in treating chronic pain conditions like neuropathic pain and migraines.
It is important to note that TCAs are associated with a range of side effects, including dry mouth, drowsiness, constipation, and blurred vision. Moreover, they require careful monitoring due to their potential for drug interactions, particularly with monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs).
Despite the availability of newer classes of antidepressants, TCAs remain an essential component of the treatment arsenal for various mental health disorders. Their well-established efficacy, along with ongoing research and development in the field, ensures that TCAs will continue to play a significant role in managing these conditions in the foreseeable future.
Opipramol DiHydrochloride (Tricyclic antidepressants), classified under Antidepressants
Antidepressants are a category of pharmaceutical Active Pharmaceutical Ingredients (APIs) widely used in the treatment of depression and other mood disorders. These medications work by balancing the levels of certain chemicals in the brain called neurotransmitters, such as serotonin, norepinephrine, and dopamine.
There are several types of antidepressants available, each with its own mechanism of action and efficacy. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed as a first-line treatment for depression. They prevent the reabsorption of serotonin, resulting in increased serotonin levels in the brain. Examples of popular SSRIs include fluoxetine, sertraline, and escitalopram.
Tricyclic antidepressants (TCAs) are another class of antidepressants that work by blocking the reuptake of both serotonin and norepinephrine. They are generally used when SSRIs are ineffective or not well-tolerated. Amitriptyline, nortriptyline, and imipramine are commonly prescribed TCAs.
Other antidepressants include serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, and monoamine oxidase inhibitors (MAOIs). SNRIs, such as venlafaxine and duloxetine, inhibit the reuptake of both serotonin and norepinephrine. Atypical antidepressants, including bupropion and mirtazapine, have diverse mechanisms of action, targeting multiple neurotransmitters. MAOIs, such as phenelzine and tranylcypromine, work by inhibiting the enzyme monoamine oxidase, which breaks down neurotransmitters.
It is important to note that antidepressants may have various side effects and require close monitoring by healthcare professionals. Dosages and treatment duration vary based on individual needs and response. Antidepressants are typically prescribed as part of a comprehensive treatment plan that may include psychotherapy and lifestyle modifications.
In conclusion, antidepressants are a vital category of pharmaceutical APIs used to manage depression and related mood disorders. They act on neurotransmitters in the brain to alleviate symptoms and improve overall well-being. It is crucial to consult with a healthcare provider to determine the most suitable antidepressant and monitor its effects.
Opipramol DiHydrochloride API manufacturers & distributors
Compare qualified Opipramol DiHydrochloride API suppliers worldwide. We currently have 3 companies offering Opipramol DiHydrochloride API, with manufacturing taking place in 2 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Edmond Pharma (Recipharm) | Producer | Italy | Italy | CoA, GMP | 20 products |
| Erregierre | Producer | Italy | Italy | CoA, GMP | 44 products |
| Zydus Takeda Healthcare | Producer | India | India | CoA, GMP | 7 products |
When sending a request, specify which Opipramol DiHydrochloride API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Opipramol DiHydrochloride API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
